



	MD (Patholog	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist		Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist	
NAME	: Mr. VIKAS				
AGE/ GENDER	: 41 YRS/MALE	PA	FIENT ID	: 1591352	
COLLECTED BY	:	RE	G. NO./LAB NO.	: 012411260003	
REFERRED BY	:	RE	GISTRATION DATE	: 26/Nov/2024 07:53 AM	
BARCODE NO.	:01521452	CO	LLECTION DATE	: 26/Nov/2024 07:55AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RE	PORTING DATE	: 26/Nov/2024 11:07AM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	6349/1, NICHOLSON ROAD, AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
	CLIN	ICAL CHEMISTR	V /DIOCHEMICT	'DV	
	CLIN			ĸı	
		LIPID PROFI			
CHOLESTEROL TO by CHOLESTEROL OX		202.69 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0	
TRIGLYCERIDES: S by GLYCEROL PHOSE	ERUM PHATE OXIDASE (ENZYMATIC)	218.43 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		29.77 ^L	mg/dL	VERY HIGH: > OR = 500.0 LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: SERUM by calculated, spectrophotometry		129.23	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0	
NON HDL CHOLES' by Calculated, spe		172.92 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTER		43.69	mg/dL	0.00 - 45.00	
by CALCULATED, SPE TOTAL LIPIDS: SEE by CALCULATED, SPE	RUM	623.81	mg/dL	350.00 - 700.00	
CHOLESTEROL/HI		6.81 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab:6349/1, Nicholson Road, Ambala Cantt - 133 001, HaryanaKOS Molecular Lab:IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana0171-2643898, +91 99910 43898care@koshealthcare.comwww.koshealthcare.comwww.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





		hopra & Microbiology) onsultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)		
NAME	: Mr. VIKAS					
AGE/ GENDER	: 41 YRS/MALE	PATI	ENT ID	: 1591352		
COLLECTED BY	:	REG.	NO./LAB NO.	: 012411260003		
REFERRED BY	:	REGI	STRATION DATE	: 26/Nov/2024 07:53 AM		
BARCODE NO.	: 01521452	COLL	ECTION DATE	: 26/Nov/2024 07:55AM		
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REPO	RTING DATE	: 26/Nov/2024 11:07AM		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT					
Test Name		Value	Unit	Biological Reference interval		
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		4.34 ^H	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0		
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		7.34 ^H	RATIO	3.00 - 5.00		

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

